Xilio reports XTX202 Phase 1/2 data: 50% disease control at ≥2.8 mg/kg, no vascular leak syndrome

Xilio Therapeutics, Inc.

62 patients dosed; 42 evaluable for activity: 31% disease control rate (13 SD ≥9 wks) across all doses, 50% at ≥2.8 mg/kg (3/6).
No signs/symptoms of vascular leak syndrome; TRAEs primarily Grade 1-2; no discontinuations due to TRAE.
Two patients on treatment >1 year (MSS CRC and RCC); dose-dependent PK with ~15% activated drug in tumor vs <1% in plasma.
Plan to evaluate XTX202 at 4.0 mg/kg in Phase 2 for melanoma and RCC; initial data expected Q2 2024.
Milestones subject to additional capital: XTX101 combo Phase 2 start Q3 2024, XTX301 data H2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.